Talphera's Q3: no revenue, a smaller per-share loss and an FDA bet on early NEPHRO enrollment close
With $14.2 million in cash and a pivotal CRRT study running short of its 70-patient target, Talphera is asking the FDA to accept a December 31, 2026 enrollment cutoff.
The quarter in numbers
Talphera is a pre-revenue specialty pharmaceutical company, and its third-quarter 2026 results show that. Revenue was zero, against $1 thousand in the third quarter of 2025. For the nine months ended September 30, 2026 it was also zero, against $28 thousand a year earlier.
Combined R&D and SG&A expenses were $4.1 million, up from $3.4 million. R&D was $2,189 thousand (Q3 2025: $1,803 thousand) and SG&A was $1,947 thousand (Q3 2025: $1,620 thousand). Loss from operations widened to $4,136 thousand from $3,422 thousand.
The net loss attributable to common shareholders still narrowed, to $4.0 million from $4.4 million. The reason sits below the operating line, as the next section shows.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Sources
- Talphera, Inc.: quarterly results release (SEC filing) SEC EDGAR · 12 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
Tonix's TONMYA reaches $15M, but a $163M cash pile and a Paragraph IV filing frame the debate
Third-quarter net product revenue rose to about $17.2M, yet opex of $72.7M and a runway only into early Q3 2027 mean financing and patent litigation loom over the launch.
ADC Therapeutics: volume-led sales and deeper cost cuts, as recapitalisation shifts focus to ASH
Q3 net product revenue of $21.0M and a 29% cut in adjusted opex narrowed the loss, while an October restructuring extended the company's expected cash runway into 2029.
Inhibrx's Q3: Debt and launch prep push losses up as chondrosarcoma review looms
A $2.0 million Pfizer licence fee barely dented a $38.7 million net loss as interest costs and pre-commercial spend rose while R&D fell and the balance sheet moved into deficit.